|3rd November 2020||Andrew A. F. Hack||5,365,659||Conversion of derivative||$0.00|
|3rd November 2020||Andrew A. F. Hack||250,000||Open or private purchase||$24.00||$6,000,000.00|
|26th October 2020||Andrew A. F. Hack||487,500||Grant/award etc.||$10.00||$4,875,000.00|
|17th July 2020||Robert Janssen||50,000||Open or private sale||$11.09||$554,500.00|
|27th May 2020||Andrew A. F. Hack||1,000,000||Open or private purchase||$5.00||$5,000,000.00|
|19th May 2020||Robert Janssen||15,000||Open or private sale||$6.33||$94,950.00|
|6th May 2020||Robert Janssen||28,000||Open or private sale||$4.52||$126,560.00|
|5th May 2020||Robert Janssen||9,000||Open or private sale||$4.43||$39,870.00|
|7th April 2020||Andrew A. F. Hack||2,800,000||Open or private purchase||$5.59||$15,652,000.00|
|7th April 2020||Andrew A. F. Hack||645,667||Open or private purchase||$7.74||$4,997,462.58|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Dynavax Technologies Corp. is a biopharmaceutical company. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996.